Key Takeaway: Precision BioSciences has announced that its partner, TG Therapeutics, has received Investigational New Drug (IND) clearance from the U.S. FDA for azer-cel, an allogeneic CAR T therapy. This marks a significant step forward in the investigation of azer-cel for treating multiple sclerosis. The approval underscores the potential of Precision's ARCUS® platform in developing gene editing therapies.
Price reaction · baseline $8.46 (2024-08-08 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Azer-cel receives IND clearance from the FDA.
Collaboration with TG Therapeutics enhances development prospects.
Potential for innovative treatment in multiple sclerosis.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. –(BUSINESS WIRE)–Aug. 9, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for
Frequently Asked Questions
What is azer-cel?
Azer-cel is an allogeneic CAR T therapy developed by Precision BioSciences.
Who received the IND clearance for azer-cel?
TG Therapeutics received the IND clearance for azer-cel from the U.S. FDA.
What disease is azer-cel being investigated for?
Azer-cel is being investigated for the treatment of multiple sclerosis.
What platform does Precision BioSciences use?
Precision BioSciences utilizes its proprietary ARCUS® platform for gene editing therapies.